P/E ratio for Genmab (GMAB)
P/E ratio as of March 2025 (TTM): 19.2
According to Genmab's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.1717. At the end of 2022 the company had a P/E ratio of 36.4.
P/E ratio history for Genmab from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 36.4 | -33.9% |
| 2021 | 55.1 | 51.51% |
| 2020 | 36.4 | -16.91% |
| 2019 | 43.8 | -0.59% |
| 2018 | 44.0 | -23.45% |
| 2017 | 57.5 | -0.95% |
| 2016 | 58.1 | -16.22% |
| 2015 | 69.3 | 9.26% |
| 2014 | 63.4 | -36.03% |
| 2013 | 99.1 | -1426.2% |
| 2012 | -7.48 | 180.52% |
| 2011 | -2.66 | -75.13% |
| 2010 | -10.7 | 202.86% |
| 2009 | -3.54 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.